The Firm represented Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, BNP Paribas Securities Corp. and Crédit Agricole Corporate and Investment Bank, as the initial purchasers in the Rule 144A/Regulation S offering of $1 billion aggregate principal amount of 5.375% Senior Guaranteed Notes due 2028 by CSC Holdings, LLC (“CSC Holdings”).
Gide has advised Extérion Média France on the dispute regarding the temporary service concession for the operation of street furniture displaying general or local information, as well as advertising, to Somupi, a company of group JC Decaux.
Davis Polk advised Millicom International Cellular S.A. on the sale to subsidiaries of Bharti Airtel Limited of its business in Rwanda, which is operated under the brand “Tigo.”
Millicom is a telecom and media company dedicated to emerging markets in Latin America and Africa, providing mobile services to more than 57 million customers. Airtel, headquartered in India, is a global telecommunications company with operations in 17 countries across Asia and Africa, ranking amongst the top 3 mobile service providers globally in terms of subscribers.
Davis Polk advised Natura Cosméticos S.A. in connection with its $750 million offering of 5.375% senior notes due 2023, which were issued pursuant to Rule 144A and Regulation S under the Securities Act.
Founded in 1969, Natura is a Brazilian multinational cosmetics manufacturer, recognized for its commitment to sustainable development, and a leader in the direct sales sector in Brazil. Natura is also the parent company of The Body Shop, an iconic British brand focusing on innovative, nature-inspired products, and of Aesop, an Australian luxury cosmetics brand.
Davis Polk advised Grupo Financiero Santander Mexico, S.A.B. de C.V. ("Grupo Financiero Santander Mexico") and Banco Santander (Mexico), S.A., Institucion de Banca Multiple, Grupo Financiero Santander Mexico ("Banco Santander (Mexico)") on Grupo Financiero Santander Mexico's merger with and into Banco Santander (Mexico), its principal subsidiary. Shareholders received one share of Banco Santander (Mexico) for each share of Grupo Financiero Santander Mexico held, and Grupo Financiero Santander Mexico ceased to exist as a separate legal entity upon consummation of the merger.
Allen & Overy LLP has advised Würzburg-based printing press manufacturer Koenig & Bauer AG ("Koenig & Bauer") in connection with a syndicated credit financing in a total amount of EUR 350 million. The financing included a EUR 150 million revolving credit facility and a EUR 200 million letter of credit facility.
The facilities have a term of five years with extension options of up to two years. This is the first transaction in the syndicated credit market for Koenig & Bauer.
King & Wood Mallesons (KWM) advised Miura Private Equity on the structuring and closing of its third fund Miura Fund III with total capital commitments of €330 million. The Fund has received strong support from a broad and global investor base of US, European and Asian institutional investors, including insurance companies, pension funds, university endowments and funds of funds, as well as local family offices.
King & Wood Mallesons (KWM) has advised Shenzhen-listed By-Health Co., Ltd. on the acquisition of Australian probiotic market leader Life-Space Group, for a purchase price of up to A$690 million.
The transaction represents By-Health’s first major outbound acquisition in the Australian healthcare industry, with Life-Space operating the Evolution Health and Ultramix businesses as well as the Life-Space brand of probiotics.
Cleary Gottlieb represented BNP PARIBAS, Citigroup, HSBC, and UBS as joint bookrunners in a Rule 144A/Reg. S offering by Korea Southern Power Co., Ltd. (KOSPO) of $400 million 3.000 percent notes due 2021.
The notes were listed on the Singapore Exchange. The offering priced on January 22, 2018, and closed on January 29, 2018.
Linklaters has advised on the issue of £750 million Bonds due 2118 (the “Bonds”) by The Wellcome Trust, the UK’s largest charitable foundation and one of the world’s largest funders of medical research. The issue of the Bonds launched and priced on 31 January 2018.
J.P. Morgan acted as lead manager and Bank of America Merrill Lynch and Morgan Stanley acted as co-managers in respect of the issue of the Bonds. Linklaters advised the Managers on the transaction.